

October 12, 2015



## Ligand to Host Analyst Day on November 18th in New York City

SAN DIEGO-- **Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)** will host an Analyst Day on Wednesday, November 18, 2015 from 10:00 a.m. to 11:30 a.m. Eastern time (7:00 a.m. to 8:30 a.m. Pacific time) in New York City.

Presenters will include:

- John Higgins, Chief Executive Officer
- Matt Foehr, President and Chief Operating Officer
- Matt Korenberg, Chief Financial Officer
- Charles Berkman, Vice President, General Counsel
- Eric Vajda, Senior Director, Preclinical Research and Development

The event will be webcast live and can be accessed at [www.ligand.com](http://www.ligand.com). A replay of this webcast will be available for 90 days following the event. For more information or to reserve a seat, please contact Daniele Johnson at [djohnson@lhai.com](mailto:djohnson@lhai.com).

### About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model focused on developing or acquiring royalty generating assets and coupling them with a lean corporate cost structure. Ligand's goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including thrombocytopenia, multiple myeloma, hepatitis, ventricular fibrillation, muscle wasting, Alzheimer's disease, dyslipidemia, diabetes, anemia, asthma, focal segmental glomerulosclerosis ("FSGS"), menopausal symptoms and osteoporosis. Ligand's Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Baxter International and Eli Lilly.

Follow Ligand on Twitter @Ligand\_LGND.

View source version on businesswire.com:

<http://www.businesswire.com/news/home/20151012005957/en/>

Ligand Pharmaceuticals Incorporated  
Todd Pettingill, 858-550-7500  
[investors@ligand.com](mailto:investors@ligand.com)

or

LHA

Bruce Voss, 310-691-7100  
[bvoss@lhai.com](mailto:bvoss@lhai.com)

Source: Ligand Pharmaceuticals Incorporated